The Food and Drug Administration accepted an application on Thursday by a rival drug maker to approve a copy-cat version of Neupogen, one of the biggest money-makers for Amgen Inc.

Sandoz, the generic drug division of Swiss pharmaceutical giant Novartis Group, has applied for approval for Zarzio, a “biosimilar” version of Neupogen...

Join our Membership to get the full story.

Are you a current Member? Sign In